跳至主要内容
临床试验/NCT04888949
NCT04888949已完成2 期

An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection

Rohto Pharmaceutical Co., Ltd.2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2021年6月15日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
15
试验地点
2
主要终点
Ventilator Free Days

研究概览

简要总结

Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.

详细描述

Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • SARS-CoV-2 infection is confirmed on antigen test or PCR test
  • Pulmonary infiltrative shadow is confirmed on chest X-ray test
  • PaO2/FiO2 <=200mmHg at the time of screening

排除标准

  • Continue treatment for Pneumonia before SARS-CoV-2 infection
  • SOFA score >= 15
  • Infection type on DIC diagnosis criteria >= 4
  • Deep Venous Thrombosis

结局指标

主要结局

Ventilator Free Days

时间窗: Day 28

Ventilator Free Days which appear in subjects with ADR-001 treatment are evaluated.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验